ABSTRACT
Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic challenge. The aim of the Endpoints for Extraintestinal Manifestations in Inflammatory Bowel Disease Trials (EXTRA) initiative was to achieve international expert consensus on how to assess these manifestations in IBD trials. A systematic literature review was done to identify methods to diagnose extraintestinal manifestations in patients with IBD and measure treatment outcomes. A consensus meeting involving a panel of 41 attendees, including gastroenterologists and referral specialists, was held on March 31, 2021, as part of an International Organization for the Study of Inflammatory Bowel Diseases initiative. The panel agreed that a specialist's expertise is needed to confirm the diagnosis of extraintestinal manifestations before the inclusion of a patient in IBD trials, except for axial spondyloarthritis, for which typical symptoms and MRI can be sufficient. Easy-to-measure endpoints were identified to assess the response of extraintestinal manifestations to treatment without needing specialist involvement. For uveitis, peripheral spondyloarthritis, and arthralgia, endpoint measurements need specialist expertise. The timing of endpoint measurements was discussed for individual extraintestinal manifestations. The EXTRA consensus proposes guidelines on how to thoroughly evaluate extraintestinal manifestations within IBD trials, and recommends that these guidelines are implemented in future trials to enable prospective assessment of these manifestations and comparison between studies.
Subject(s)
Inflammatory Bowel Diseases/complications , Clinical Trials as Topic , Eye Diseases/etiology , Humans , Rheumatic Diseases/etiology , Skin Diseases/etiologyABSTRACT
OBJECTIVE: The purpose of this study was to assess the incidence of nephrogenic systemic fibrosis (NSF) before and after educational interventions, implementation of a clinical screening process, and change to gadobenate dimeglumine in patients who had an estimated glomerular filtration rate (eGFR) of 30 mL/min per 1.72 m or less. METHODS: This is a Health Insurance Portability and Accountability Act compliant, institutional review board exempt study. Two periods were studied-July 2005 to June 2006, during which gadodiamide was utilized as our magnetic resonance (MR) contrast agent, and November 2006 to August 2014, during which gadobenate dimeglumine was used as our MR contrast agent in patients who had an eGFR 30 mL/min per 1.72 m or less. In addition to a change in the MR contrast agent, education of our staff physician to the risks of NSF with MR contrast agents and the implementation of a clinical screening process occurred. The rate of NSF before and after the interventions was compared using the χ test. RESULTS: There was a statistically significant difference in the incidence of NSF in patients with an eGFR 30 mL/min per 1.72 m or less between the 2 periods: July 2005 to June 2006, 6 of 246 patients were diagnosed with NSF (P < 0.001), versus November 2006 to August 2014, 0 of 1423 patients were diagnosed with NSF. CONCLUSIONS: Our data demonstrates a marked decrease in the incidence of NSF after education of our referring physicians, implementation of clinical screening process, and change to gadobenate dimeglumine from gadodiamide in patients with renal insufficiency. This approach potentially provides an acceptable risk-benefit profile for patients with renal insufficiency that required MR imaging for clinical care.
Subject(s)
Contrast Media/adverse effects , Gadolinium DTPA/adverse effects , Meglumine/analogs & derivatives , Nephrogenic Fibrosing Dermopathy/epidemiology , Organometallic Compounds/adverse effects , Renal Insufficiency/diagnosis , Renal Insufficiency/epidemiology , Comorbidity , Glomerular Filtration Rate/physiology , Humans , Image Enhancement/methods , Incidence , Magnetic Resonance Imaging , Meglumine/adverse effects , Nephrogenic Fibrosing Dermopathy/physiopathology , Renal Insufficiency/physiopathology , Retrospective Studies , Risk Assessment/methods , Risk FactorsABSTRACT
IMPORTANCE: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignant neoplasm with cutaneous manifestations and a rapidly progressive clinical course. The diagnosis relies on characteristic clinicopathologic and immunopathologic features. However, the overlap of immunophenotypic features with other cancers, as well as newly discovered interpersonal and intrapersonal phenotypic variations, renders the identification of BPDCN challenging. A greater understanding of the proteins expressed by BPDCN might facilitate its recognition and provide insights into its clinical behavior. OBSERVATIONS: In 7 of 9 patients at 4 tertiary care institutions, immunohistochemical analysis demonstrated strong CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) expression by neoplastic cells. Combined with similar findings observed in 1 former patient, 8 of 10 cases of BPDCN were CD31/PECAM-1 positive. CONCLUSIONS AND RELEVANCE: Expression of CD31/PECAM-1 by BPDCN adds new information about the antigenic profile of this unusual neoplasm. CD31/PECAM-1 influences multiple cell functions including adhesion, apoptosis, coagulation, host response, and protein synthesis that might affect clinical features of BPDCN such as hemorrhage, aggressive tumor growth, and resistance to therapy. Therefore, the potential role of this molecule in the tumor formation and progression of BPDCN warrants additional exploration.
Subject(s)
Dendritic Cells/pathology , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Skin Neoplasms/pathology , Aged, 80 and over , Disease Progression , Humans , Immunohistochemistry , Male , PhenotypeABSTRACT
African tick bite fever (ATBF) is a rickettsial infection that should be considered as the cause of fever in travelers returning from endemic regions of sub-Saharan Africa or the Caribbean. Patients typically present with a flu-like syndrome and may demonstrate one or more cutaneous inoculation eschars as a diagnostic key. We present a case of ATBF in a pregnant woman following her trip to Swaziland. Her symptoms rapidly improved with institution of effective antimicrobial treatment with azithromycin and rifampin; she made a full recovery.
Subject(s)
Pregnancy Complications, Infectious/microbiology , Rickettsia Infections/microbiology , Skin Diseases/microbiology , Tick Bites/complications , Adult , Eswatini , Female , Humans , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Rickettsia Infections/diagnosis , Skin Diseases/pathology , TravelABSTRACT
A variety of systemic disorders--infections, noninfectious inflammatory diseases, collagen vascular diseases, hereditary diseases, and acquired immune deficiency diseases--may affect both the skin and the lung. The findings in one organ system can help establish the diagnosis or limit the differential diagnosis. Cutaneous manifestations of many conditions (eg, Kaposi sarcoma) precede thoracic manifestations and sometimes have prognostic implications for respiratory disease; in other conditions (eg, organizing pneumonia in polymyositis and dermatomyositis), thoracic manifestations precede cutaneous ones. When skin and thoracic manifestations develop simultaneously, as occurs in the acute form of sarcoidosis known as Löfgren syndrome, the diagnosis is often readily established. Familiarity with the appearances of skin lesions that are commonly associated with systemic lung disease, especially those that are disease specific, may allow the radiologist to pinpoint a diagnosis even when thoracic imaging findings are nonspecific.
Subject(s)
Lung Diseases/diagnostic imaging , Lung Diseases/etiology , Radiography, Thoracic , Skin Diseases/diagnostic imaging , Skin Diseases/etiology , Tomography, X-Ray Computed , Blastomycosis/complications , Blastomycosis/diagnostic imaging , Dermatomyositis/complications , Dermatomyositis/diagnostic imaging , Diagnosis, Differential , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/diagnostic imaging , Genetic Diseases, Inborn/complications , Genetic Diseases, Inborn/diagnostic imaging , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnostic imaging , Polymyositis/complications , Polymyositis/diagnostic imaging , Sarcoidosis/complications , Sarcoidosis/diagnostic imaging , Sarcoma, Kaposi/complications , Sarcoma, Kaposi/diagnostic imaging , Scleroderma, Systemic/complications , Scleroderma, Systemic/diagnostic imagingABSTRACT
Nephrogenic systemic fibrosis is a rare fibrosing disorder associated with the use of gadolinium-based contrast agents in patients with renal dysfunction. However, only a small proportion of at-risk patients develops the disorder, and the exact determinants of disease are still not completely clear. Here, we present an update on emerging evidence for the role of gadolinium-based contrast agents, renal dysfunction, and background inflammation in disease expression, with a focus on current experimental models. Based on these findings, significant progress has been made in our understanding of the pathophysiology of this disorder over the last few years. This review provides a summary of these developments with discussion of the implications for clinical practice and directions for additional study.
Subject(s)
Evidence-Based Medicine , Nephrogenic Fibrosing Dermopathy/etiology , Nephrogenic Fibrosing Dermopathy/physiopathology , Contrast Media/adverse effects , Gadolinium/adverse effects , Humans , Inflammation/physiopathology , Renal Insufficiency/complications , Renal Insufficiency/physiopathology , Risk FactorsSubject(s)
Angiofibroma/drug therapy , Facial Neoplasms/drug therapy , Immunosuppressive Agents/administration & dosage , Sirolimus/administration & dosage , Tuberous Sclerosis/complications , Administration, Topical , Adolescent , Angiofibroma/diagnosis , Angiofibroma/etiology , Cheek , Diagnosis, Differential , Facial Neoplasms/diagnosis , Facial Neoplasms/etiology , Female , Follow-Up Studies , Humans , Tuberous Sclerosis/drug therapyABSTRACT
OBJECTIVES: To examine choroidal melanomas for genomic instability, manifested by microsatellite instability (MSI) and mismatch repair (MMR) protein alterations, and to determine the association of these alterations with selected clinicopathological features of the tumors. METHODS: Polymerase chain reaction-based microsatellite assays were applied to analyze 57 cases of choroidal melanomas using 11 microsatellite markers at 5 chromosomal regions: 1p, 2p, 4q, 9p, and 17p. Immunoperoxidase staining methods and mouse monoclonal antibodies were used to investigate the expression patterns of MMR proteins. RESULTS: Microsatellite instability was found at the 1p, 9p, and 17p regions in these lesions with an overall prevalence of 35% (20/57). The frequency of MSI ranged from 9% (1/11) to 27% (3/11), ie, low-level MSI (MSI-L). The instability was most commonly found at the 1p region (D1S2734, 55%; D1S2832, 40%; and D1S233, 20%). Two MSI banding patterns, band shifts and the appearance of additional bands, were found in 10% and 90% of the unstable lesions, respectively. The average percentages of hMLH1 and hMSH2 positively stained cells were insignificantly reduced in the unstable lesions (81.7 +/- 9.3 and 76.7 +/- 16.7) as compared with the stable lesions (84.1 +/- 15.5 and 78.6 +/- 19.6; P = .62 and 0.74 for hMLH1 and hMSH2, respectively). There was no significant difference in survival between the 2 groups; however, relative to the stable subset, the unstable tumors showed a trend (P<.10) toward occurring at a younger age and having tumor cells in vascular lakes. CONCLUSIONS: The presence of MSI-L in some choroidal melanomas defines a novel genetic subset of these tumors and suggests that MSI (genomic instability) may play a role in their molecular pathogenesis. Elucidation of the underlying mechanisms for MSI will require further investigation. CLINICAL RELEVANCE: Detection of the MSI-L pattern might prove to be useful as an adjunct to the conventional diagnosis of choroidal melanomas. Larger series are needed to determine whether any of the correlative trends noted in this study will achieve statistical significance. To the best of our knowledge, this study is the first to define both the MSI and MMR protein expression features of choroidal melanomas.
Subject(s)
Choroid Neoplasms/genetics , DNA, Neoplasm/genetics , Genomic Instability , Melanoma/genetics , Microsatellite Repeats/genetics , MutS Homolog 2 Protein/genetics , Proteins/genetics , Base Pair Mismatch/genetics , Choroid Neoplasms/metabolism , Female , Humans , Immunoenzyme Techniques , Male , Melanoma/metabolism , Middle Aged , MutS Homolog 2 Protein/metabolism , Proteins/metabolism , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Melanoma cells can undergo self-destruction via programmed cell death, i.e. apoptosis. In these tumours, the molecular components of apoptosis include positive (apoptotic) and negative (anti-apoptotic) regulators. The former include p53, Bid, Noxa, PUMA, Bax, TNF, TRAIL, Fas/FasL, PITSLRE, interferons, and c-KIT/SCF. The latter include Bcl-2, Bcl-X(L), Mcl-1, NF-(K)B, survivin, livin, and ML-IAP. Alternatively, some molecules such as TRAF-2, c-Myc, endothelins, and integrins may have either pro- or anti-apoptotic effects. Some of these molecules are of potential therapeutic use, such as: (1) p53, which influences resistance to chemotherapy; (2) Mcl-1 and Bcl-X(L), which can override apoptosis; (3) TRAIL, which has selective fatal effects on tumour cells; (4) NF-(K)B, which when downregulated sensitizes cells to TRAIL and TNF; (5) the PITSLRE kinases, whose alteration appears to result in Fas resistance; (6) interferons, which sensitize cells to other factors; and (7) survivin and other IAPs that inhibit apoptosis. This review summarizes the state of current knowledge about the key molecular components and mechanisms of apoptosis in melanoma, discusses potential therapeutic ramifications, and provides directions for future research.